

# Lifecare: A step forward under the product development agreement with Sanofi

Lifecare Research Note 2024-10-29 09:42

Redeye comments on Lifecare following today's news that the company has completed a key development phase and submitted a phase-end report to Sanofi, which holds a right of first refusal for Sencell in human use.




Filip Einarsson

In today's press release, Lifecare confirmed the completion of a "defined development phase," which triggers the release of funding from Sanofi under their existing product development agreement. A similar event occurred in Q3 2023, see this [note](#). The total agreement provides a funding contribution of approximately EUR0.3m; therefore, today's contribution is not expected to have any substantial impact on Lifecare's income statement for Q4.

In exchange for Sanofi's financial contribution to the product development agreement, Lifecare has granted Sanofi a right of first refusal to negotiate a global and exclusive license for Lifecare's patented and proprietary glucose monitoring technology for human use.

Interestingly, the press release states that Lifecare anticipates submitting the next phase-end report after concluding the longevity study in dogs, projected for Q1 2025. The company also notes that "this report could potentially activate commercial rights." However, Lifecare clarifies that there is currently no indication as to whether these commercial rights will indeed be triggered, but in our view it highlights the potential for an interesting newsflow throughout the first half of 2025.

Today's press release does not impact our valuation of Lifecare; however, in this note we have adjusted our valuation model to account for the newly issued shares from the recent share issue. This adjustment results in a revised base case of NOK43, previously NOK47.



### REDEYE QUALITY RATING

3	3	0
People	Business	Financials

### FAIR VALUE RANGE

Price 18.0

Bear 12.0 Bull 128

Base 43.0

### TIMELINESS

5

### KEY STATS

Market Cap	285.3 MNOK
Entprs. Value (EV)	227.4 MNOK
Net Debt (2024e)	-57.8 MNOK
30 Day Avg Vol	38 K
Shares Outstanding	15.9M
Price / Earnings	N/A
PEG	N/A
Dividend Yield	N/A

Data from 2024-10-29 09:43

### IMPORTANT INFORMATION

All information regarding limitation of liability and potential conflicts of interest can be found at the end of the report.

Redeye, Mäster Samuelsgatan 42, 10tr, Box 7141, 103 87 Stockholm. Tel. +46 8-545 013 30  
E-post: [info@redeye.se](mailto:info@redeye.se)

## Disclaimer

### Important information

Redeye AB ("Redeye" or "the Company") is a specialist financial advisory boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the technology and life science sectors. We provide services within Corporate Broking, Corporate Finance, equity research and investor relations. Our strengths are our award-winning research department, experienced advisers, a unique investor network, and the powerful distribution channel redeye.se. Redeye was founded in 1999 and since 2007 has been subject to the supervision of the Swedish Financial Supervisory Authority.

Redeye is licensed to; receive and transmit orders in financial instruments, provide investment advice to clients regarding financial instruments, prepare and disseminate financial analyses/recommendations for trading in financial instruments, execute orders in financial instruments on behalf of clients, place financial instruments without position taking, provide corporate advice and services within mergers and acquisition, provide services in conjunction with the provision of guarantees regarding financial instruments and to operate as a Certified Advisory business (ancillary authorization).

### Limitation of liability

This document was prepared for information purposes for general distribution and is not intended to be advisory. The information contained in this analysis is based on sources deemed reliable by Redeye. However, Redeye cannot guarantee the accuracy of the information. The forward-looking information in the analysis is based on subjective assessments about the future, which constitutes a factor of uncertainty. Redeye cannot guarantee that forecasts and forward-looking statements will materialize. Investors shall conduct all investment decisions independently. This analysis is intended to be one of a number of tools that can be used in making an investment decision. All investors are therefore encouraged to supplement this information with additional relevant data and to consult a financial advisor prior to an investment decision. Accordingly, Redeye accepts no liability for any loss or damage resulting from the use of this analysis.

### Potential conflict of interest

Redeye's research department is regulated by operational and administrative rules established to avoid conflicts of interest and to ensure the independence of its analysts. The following applies:

- For companies that are the subject of Redeye's research, the applicable rules include those established by the Swedish Financial Supervisory Authority pertaining to investment recommendations and the handling of conflicts of interest. Furthermore, Redeye employees are not allowed to trade in financial instruments of the company in question, from the date research is initiated until it is published.
- An analyst may not engage in corporate finance transactions without the explicit approval of management and may not receive a remuneration directly linked to such transactions.
- Readers of these reports should assume that Redeye may have received or will receive remuneration from the company/companies cited in the report for the performance of financial advisory services. Such remuneration is of a predetermined amount and is not dependent on the content of the research.

### Redeye's research coverage

Redeye's research analyses consist of case-based analyses, which imply that the frequency of the analytical reports may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

### Recommendation structure

Redeye does not issue any investment recommendations for fundamental analysis. However, Redeye has developed a proprietary analysis and rating model, Redeye Rating, in which each company is analyzed and evaluated. This analysis aims to provide an independent assessment of the company in question, its opportunities, risks, etc. The purpose is to provide an objective and professional set of data for owners and investors to use in their decision-making.

### Duplication and distribution

This document may not be duplicated, reproduced or copied for purposes other than personal use. The document may not be distributed to physical or legal entities that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

Copyright Redeye AB.

---

## CONFLICT OF INTERESTS

Filip Einarsson owns shares in the company : No.

Redeye performs/has performed services for Lifecare and receives/has received compensation from these Companies in connection with this.